Tagged with Neurology

Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019.   The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…

Belgium Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt also delivers a clear message about the importance of continued public and private investments in basic research to foster new…

France Newly-appointed general manager of UCB France, Catherine Rives, discusses what drew her back to the company after time away, market access issues in France and the future of personalized medicine.   My mission is very clearly to raise the profile of the French affiliate within the UCB Group and simultaneously…

UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…

UK Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia research, the strengths and weaknesses of the UK’s medical research environment, and the potential effects of Brexit.   In all…

Switzerland Alessandro di Napoli, CEO of Swiss family-owned pharmaceutical group, TRB Chemedica, discusses the company’s focus on the rheumatology, ophthalmology and neurology niches and the importance of ‘Swissness’ within its internationalization process. TRB Chemedica is a family business set up by your father Guido in 1980, now counting 700 employees globally…

USA In 2016, rumours of a weakening FDA followed a disappointing 16 new drugs approved for the full year. However, since the beginning of 2017 the FDA has approved 26 drugs; double the amount of the mid-year average since 2007. “The eight oncology treatments approved by the FDA this year represent…

Greece Appointed in the midst of the Greek economic crisis, compounded by significant changes at the corporate Merck brand, Merck Greece’s MD, Konstantinos Kofinas, did not shy away from challenges. He speaks about his leadership approach, Merck’s key therapeutic areas in Greece, as well as industry collaboration in creating a sustainable…

Pharma Alberto Gugliemo, President of the Carlo Besta Institute in Milan, shares the changing perception of neurological diseases and neurological science in Italy, the nature of the institute’s collaboration with the industry and the importance of easing regulations surrounding the hire of scientists. As president of Italy’s leading scientific institute for…

Pharma Pascal Brossard, the Managing Director of Zambon France and President of Afipa (Association for the French self-medication medicines industry), reveals why he is confident that the self-medication market in France will witness substantial growth in the years ahead; and how as a family-run Italian company Zambon has a long-term vision,…

pharma Thomas Würdinger, winner of the 2014 Galenus prize, discusses his research team’s efforts to developing new treatment options and protocols for brain cancers, and the need for greater attention and investment in brain cancer treatment development, an area he identifies as the greatest unmet medical need in the field of…

Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…